Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

48.68 -1.24 (-2.48%)
Streaming Delayed Price Updated: 12:10 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish ↗
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates. 
Via Stocktwits
News headline image
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today ↗
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool
News headline image
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
News headline image
The State of Weight Loss Drugs ↗
Via The Motley Fool
News headline image
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. ↗
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
News headline image
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Structure Therapeutics Stock Was Stumbling This Week ↗
Via The Motley Fool
News headline image
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst ↗
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
News headline image
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
News headline image
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
News headline image
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
Via Investor's Business Daily
News headline image
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
News headline image
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
Via MarketBeat
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.